Composite 30-day composite end point of death or myocardial (re-)infarction in the four GPIIb-IIIa unstable ischemic syndrome trials.

Efficacy data are not provided for the low-dose eptifibatide group PURSUIT and the tirofiban plus placebo group PRISM PLUS treatment arms, which were discontinued before completion of the trials.

^*p = 0.03 in PRISM PLUS did not reach the prespecified level of p = 0.025 for a three-group trial.

† Heparin use in PURSUIT was encouraged, but not mandated, and was administered to 89.9% and 89.7% of patients randomized to placebo and eptifibatide, respectively.

Abbreviations: PARAGON, Platelet Iib/IIIa Antagonisms for the Reduction of Acute Coronary Syndrome events in the Global Organization Network; PRISM PLUS, Platelet Receptor Inhibition in the Ischemic Syndrome Management sin Patients Limited by Unstable Signs; PURSUIT, Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.

Reproduced with permission from Lincoff et al. JACC. 2000;35:1103.